Harlow, United Kingdom

Riccardo Novelli


Average Co-Inventor Count = 7.8

ph-index = 2

Forward Citations = 14(Granted Patents)


Company Filing History:


Years Active: 2008-2011

Loading Chart...
7 patents (USPTO):Explore Patents

Title: The Innovative Mind of Riccardo Novelli

Introduction: Riccardo Novelli, an accomplished inventor based in Harlow, GB, has made significant contributions to the field of pharmaceuticals with a total of seven patents to his name. His work primarily focuses on the development of orexin receptor antagonists, which have promising applications in various therapeutic areas.

Latest Patents: Among Riccardo's latest innovations are two notable patents related to piperidine compounds. The first patent, titled "Piperidine compounds for use as orexin receptor antagonist," explores N-aroyl cyclic amine derivatives and their potential use as pharmaceuticals, particularly as orexin receptor antagonists. The second patent, "N-aroyl cyclic amine derivatives as orexin receptor antagonists," provides a detailed disclosure of N-aroyl cyclic amine derivatives and their pharmacological applications in targeting orexin receptors. These inventions highlight Riccardo's expertise in medicinal chemistry and contribute to the ongoing research in treating sleep disorders and other related conditions.

Career Highlights: Riccardo Novelli is currently employed at SmithKline Beecham Corporation, where he utilizes his vast knowledge and skills to advance pharmaceutical research. His dedication to innovation has positioned him as a key figure in the development of effective treatment modalities, greatly impacting patient care and therapeutic outcomes.

Collaborations: Throughout his career, Riccardo has collaborated with talented professionals such as Wai Ngor Chan and Amanda Johns. These partnerships amplify the innovative spirit and creativity within the team, leading to groundbreaking discoveries and advancements in the pharmaceutical domain.

Conclusion: Riccardo Novelli's journey as an inventor is marked by a commitment to enhancing medical science through innovative solutions. His contributions, particularly in the realm of orexin receptor antagonists, demonstrate his significant role in shaping the future of pharmaceuticals. As he continues to push the boundaries of innovation, Riccardo remains a vital asset to SmithKline Beecham Corporation and the wider scientific community.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…